August 06, 2025

New Preventive Option Approved for Pediatric Migraine

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.

Conexiant

July 08, 2025

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

Ophthalmic Professional

August 04, 2025

Beta-HPV–Driven SCC Resolved After TCR Signaling Correction

Case study shows cutaneous squamous cell carcinoma linked to beta-human papillomavirus cleared following T-cell immune restoration.

Conexiant

August 04, 2025

Nitazenes: A Hidden Threat Stronger Than Fentanyl

The drug can be hundreds of times stronger than heroin and up to five times more potent than fentanyl.

Conexiant

August 01, 2025

Physicians Urged to Defend USPSTF Role

The Colorectal Cancer Alliance and partners are urging the Department of Health and Human Services to preserve U.S. Preventive Services Task Force’s evidence-based role in safeguarding access to no-cost colorectal cancer screening.

Conexiant

July 31, 2025

FDA Approves Implantable Device for RA

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases."

Conexiant

July 24, 2025

HHS Ends Thimerosal Use in Flu Vaccines

The U.S. Department of Health and Human Services has adopted a CDC advisory panel recommendation to remove thimerosal from all influenza vaccines, transitioning entirely to mercury-free, single-dose formulations.

Conexiant

July 23, 2025

Are Wearables Mining the Mind?

As neurotech devices move from clinics to consumers, states are racing to safeguard brainwave data from earbuds, sleep trackers, and AI-powered apps—raising new questions about privacy, consent, and medical ethics.

KFF Health News

July 23, 2025

FDA Grants Breakthrough Status to Melanoma Test

The FDA has granted Breakthrough Device designation to Castle Biosciences’ DecisionDx-Melanoma test, a gene expression profile assay designed to improve risk stratification and personalized care in cutaneous melanoma.

Conexiant